Evaluating single antiplatelet therapy after stent implantation for brain aneurysms
Official title: A Single-center, Prospective, Cohort Study of the Safety and Efficacy of Single Antiplatelet Therapy After Pipeline Flex with Shield Stent Implantation for Intracranial Aneurysms
Run by Xuanwu Hospital, Beijing · NCT06474884 · Data updated 2026-11-12
This study is testing whether taking one type of blood-thinning medication after getting a stent for brain aneurysms is safe and effective for patients with unruptured aneurysms.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 165 (estimated) |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 30, 2024 |
| Study ends | December 30, 2025 |
| Registry record updated | December 10, 2024 |
| Trial ID | NCT06474884 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with unruptured intracranial aneurysms who have undergone successful Pipeline Flex with Shield stent implantation.
✕Probably not a fit
Patients with recurrent aneurysms or those who have undergone previous interventional treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the safety and efficacy of single antiplatelet therapy following the implantation of the Pipeline Flex with Shield stent in patients with unruptured intracranial aneurysms. It is a single-center, prospective cohort study that will follow participants for a period of six months post-implantation. The study includes patients who meet specific vascular conditions and have a successful stent placement, while excluding those with recurrent aneurysms or irregularly shaped aneurysms.
Why it matters
Potential benefit: If successful, this study could provide insights into safer and more effective treatment options for patients with intracranial aneurysms.
How similar studies have gone: While there may be studies on antiplatelet therapy in similar contexts, this specific approach with the Pipeline Flex with Shield stent is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with unruptured intracranial aneurysms who received the intracranial Pipeline Flex with Shield stent. 2. Vascular conditions: 1\) There was no obvious calcification and stenosis of the parent artery. 2) The curvature of the bearing artery is minimal. 3) The parent artery diameter ≥2.5mm 3.According to the committee's assessment, only one Pipeline flex with shield is needed for aneurysm treatment. 4.Before the stent implantation procedure, standard dual antiplatelet therapy should be administered for at least 3 days. 5.Patients with an Modified Rankin Scale(mRS) score of less than 2 on the day of registration. 6.The operation was successful, and immediate postoperative angiography indicated good wall apposition. Exclusion Criteria: 1. Patients with recurrent aneurysms after interventional treatment or surgical clipping. 2. The patient after stent placement surgery. 3. Aneurysms can have irregular shapes, such as fusiform, blister-type, or dissecting aneurysms. 4. The patient had no history of stroke or aneurysm rupture in the last 3 months. 5. Abnormal platelet function, or platelet count \< 100,000 cells/mm³. 6. Known history of allergy to clopidogrel or heparin.
Where it's running
-
Xuanwu Hospital, Capital Medical University
Beijing, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
See if multimodal biomarkers can map changes from mild cognitive impairment to dementia
This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.
-
Satralizumab in the early treatment of NMOSD attacks: a multicenter real-world study
This study tests whether starting Satralizumab during an NMOSD attack is safe and helpful for adults with AQP4-IgG–positive NMOSD.
-
Real-World Experience With the WEB Device for Intracranial Aneurysms
This study tests how well the Woven EndoBridge device works in routine treatment of intracranial aneurysms in China across multiple centers.
-
Multicenter Registry of Intracranial Dural Arteriovenous Fistulas in China
This study will collect and analyze data from many hospitals in China to see how common intracranial dural AV fistulas are, how they’re treated, and what outcomes look like for patients.
-
Preventive Analgesia With Anrikefon in Laparoscopic Gallbladder Surgery
This study tests whether giving Anrikefon before or during laparoscopic cholecystectomy can reduce early postoperative pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.